Karen Anderson's most recent trade in Centessa Pharmaceuticals plc - ADR was a trade of 30,526 Share Option (right to buy) done . Disclosure was reported to the exchange on Feb. 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 30,526 | 244,464 | - | - | Share Option (right to buy) | |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.01 per share. | 07 Feb 2025 | 30,526 | 84,848 | - | 4.0 | 122,409 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Sale of securities on an exchange or to another person at price $ 19.03 per share. | 07 Feb 2025 | 30,526 | 54,322 | - | 19.0 | 580,797 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Sale of securities on an exchange or to another person at price $ 18.99 per share. | 07 Feb 2025 | 429 | 54,322 | - | 19.0 | 8,147 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 429 | 244,035 | - | - | Share Option (right to buy) | |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.01 per share. | 07 Feb 2025 | 429 | 54,751 | - | 4.0 | 1,720 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 120,000 | 120,000 | - | - | Share Option (right to buy) | |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.92 per share. | 01 Feb 2025 | 10,732 | 60,793 | - | 16.9 | 181,585 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Sale of securities on an exchange or to another person at price $ 16.86 per share. | 01 Feb 2025 | 6,471 | 54,322 | - | 16.9 | 109,124 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2024 | 10,624 | 43,510 | - | - | Share Option (right to buy) | |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Sale of securities on an exchange or to another person at price $ 17.32 per share. | 13 Dec 2024 | 10,624 | 71,525 | - | 17.3 | 184,036 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 13 Dec 2024 | 10,624 | 82,149 | - | 3.8 | 40,902 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Sale of securities on an exchange or to another person at price $ 17.01 per share. | 13 Dec 2024 | 5,876 | 71,525 | - | 17.0 | 99,974 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2024 | 5,876 | 54,134 | - | - | Share Option (right to buy) | |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 13 Dec 2024 | 5,876 | 77,401 | - | 3.9 | 22,623 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Sale of securities on an exchange or to another person at price $ 11.66 per share. | 25 Mar 2024 | 29,995 | 92,690 | - | 11.7 | 349,625 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.01 per share. | 25 Mar 2024 | 25,010 | 102,695 | - | 4.0 | 100,290 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 25,010 | 274,990 | - | - | Share Option (right to buy) | |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Sale of securities on an exchange or to another person at price $ 12.21 per share. | 25 Mar 2024 | 21,165 | 71,525 | - | 12.2 | 258,336 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 25 Mar 2024 | 19,990 | 122,685 | - | 3.9 | 76,962 | Ordinary Shares |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 19,990 | 60,010 | - | - | Share Option (right to buy) | |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 125,000 | 125,000 | - | - | Share Option (right to buy) | |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 31,250 | 84,950 | - | 0 | Ordinary Shares | |
| Centessa Pharmaceuticals p... | Karen Anderson | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.19 per share. | 01 Feb 2024 | 7,265 | 77,685 | - | 8.2 | 59,500 | Ordinary Shares |